Skip to main content

RFA for Barrett’s - a day-case burn, not a resection.

Endoscopic radiofrequency ablation with the HALO / Barrx platform - circumferential balloon and focal paddle - for confirmed dysplastic Barrett’s. Consultant-led lists, dual-pathologist review, and a proper CE-IM programme.

See indicative pricing
A radiographer guides a patient onto the bed of an advanced 3 Tesla MRI scanner in a London imaging suite

Indicative pricing

What private HALO / Barrx ablation costs in the UK.

Indicative ranges across UK Barrett’s units.

In short

£3,000–£7,000, home the same day.

Procedure Indicative range
Diagnostic gastroscopy with Barrett’s biopsies £900–£1,400
Circumferential RFA (Barrx 360 Express) £4,500–£7,000
Focal RFA (Barrx 90 catheter) £3,000–£5,000
EMR of visible lesion + RFA (combined) £5,500–£9,000
Full CE-IM programme (typical 3–4 sessions) £12,000–£22,000
Second-pathologist dysplasia review £350–£600
Upper-GI consultant consultation only £250–£450

Prices vary by hospital, by the endoscopist, and by the length of the Barrett’s segment - long-segment C≥5 disease usually needs a circumferential session first, then focal touch-ups. Combined EMR and RFA cases are always the top of the range.

The problem

The right diagnosis, the right platform, and a proper eradication programme.

Barrett’s ablation is where general endoscopy quietly under-delivers - low-grade dysplasia over-called, visible lesions missed, single sessions marketed as a cure. We fix all three before the first burn.

  • Confirm dysplasia twice before you ablate

    Two independent GI pathologists must agree. Inter-observer variability for LGD is huge - dual reporting stops overtreatment.

  • Look for a nodule before you burn a segment

    Any visible lesion needs EMR or ESD first for histology and staging. Blind ablation over a nodule is a hard error to undo.

  • Plan a programme, not a single session

    CE-IM takes three to four sessions on average, plus lifelong surveillance. Anyone quoting a one-off cure is selling.

When it helps

When RFA for Barrett’s is the right step.

The situations we see most, plus the one red flag that needs an urgent upper-GI review rather than a routine booking.

  • Confirmed low-grade dysplasia in Barrett’s

    LGD confirmed by two GI pathologists on a repeat, PPI-healed endoscopy - UK and BSG guidance now favours ablation over surveillance for confirmed LGD.

  • High-grade dysplasia without a visible lesion

    Flat HGD on random biopsies once a visible nodule has been excluded. RFA is the standard of care.

  • Residual Barrett’s after EMR

    After endoscopic mucosal resection of a nodule, the flat residual Barrett’s segment is ablated to reduce metachronous neoplasia risk.

  • Intramucosal (T1a) adenocarcinoma - after EMR

    For fully resected T1a cancer, RFA of the residual Barrett’s completes eradication and lowers the risk of a second focus.

  • Recurrent intestinal metaplasia after prior ablation

    Small tongues or islands that reappear at the neo-Z-line - focal RFA treats these quickly, often in a single session.

  • Long-segment Barrett’s (C≥3) in a fit patient

    Long segments are treated in stages - circumferential first, then focal touch-ups until CE-IM.

  • Patient preference over oesophagectomy

    For HGD and T1a disease, endoscopic ablation is preferred to surgical resection where feasible - fewer complications, no organ loss.

  • Red flag: nodule, ulcer or stricture on endoscopy

    Any visible lesion needs EMR or ESD first - never blind ablation. Weight loss, dysphagia or GI bleeding needs urgent upper-GI review, not a routine booking.

Procedure options

Platform and pathway depend on the segment length and any nodule.

What each option involves - catheter (360 balloon, 90 paddle, Ultra, channel) and pathway (EMR first, cryo alternative, hybrid APC).

  • Circumferential RFA (Barrx 360 Express)

    A self-sizing balloon delivers a uniform 360-degree burn to a 4 cm segment at a time. The workhorse for long-segment or full-circumference Barrett’s.

  • Focal RFA (Barrx 90 catheter)

    A 90-degree paddle mounted on the endoscope treats residual tongues, islands and the neo-Z-line. Used at every touch-up session.

  • Ultra-focal RFA (Barrx 60/Ultra)

    Smaller footprint for very short residual areas or tight anatomy - minimises collateral thermal injury.

  • Channel RFA (through-the-scope)

    A through-the-channel catheter for awkward positions where a paddle will not sit - useful at the hiatus or in a tortuous oesophagus.

  • EMR then RFA (combined pathway)

    Any visible lesion is first resected by endoscopic mucosal resection for histology and staging. RFA then treats the flat residual Barrett’s at a later session.

  • Cryoablation (alternative platform)

    Nitrous-oxide or liquid-nitrogen cryotherapy is an accepted alternative where RFA is not tolerated or the segment is unusually irregular.

  • Hybrid APC (argon plasma coagulation)

    Submucosal saline lift followed by APC - a lower-cost option for short-segment disease in selected units.

Safety and recovery

What to expect afterwards - honestly.

RFA is a mature, well-studied endoscopic treatment. The things worth planning are the strictures that occasionally follow, and the long tail of surveillance.

  • Sedation, not general anaesthetic in most cases

    Conscious sedation with fentanyl and midazolam, or propofol for anxious patients. A qualified sedationist is present throughout. Day-case in almost every case.

  • Chest discomfort and odynophagia for a few days

    A dull retrosternal ache and painful swallowing for 3–5 days are the rule, not the exception. Soft diet, high-dose PPI, sucralfate suspension and paracetamol control it.

  • Stricture formation - the main long-term risk

    A benign narrowing at the treated segment develops in around 5–8 percent of cases. Almost all respond to one or two balloon dilatations at follow-up gastroscopy.

  • Bleeding is uncommon

    Clinically significant bleeding after RFA occurs in under 1 percent of cases. It is much more common after EMR than after ablation alone.

  • Perforation is very rare

    Full-thickness injury is under 1 in 500. Recognised on the table it is usually managed endoscopically with clips; a small minority need surgery.

  • Buried glands and incomplete response

    Around 5 percent of patients develop intestinal metaplasia buried under new squamous mucosa. Systematic biopsy of the neo-Z-line at surveillance picks this up.

  • Recurrence is real - surveillance is not optional

    Even after CE-IM, recurrence runs at roughly 5–8 percent per year. Skipping surveillance endoscopy is the single biggest post-ablation risk.

  • PPI for life after ablation

    Twice-daily PPI is standard after RFA to keep reflux under control. Anti-reflux surgery is discussed for patients with breakthrough symptoms on maximum medical therapy.

  • Red flags after treatment

    Fever, chest or back pain that worsens, breathlessness, vomiting blood or black stools need the same-day team or A&E - not a routine call.

Reading your endoscopy report

Your ablation report in four parts. Read the last one first.

Whichever platform was used - Barrx 360, 90 focal or Ultra - the note the endoscopist sends you keeps to the same shape.

A UK consultant gastroenterologist reviewing an endoscopy report

A quiet reminder

Endoscopy language is precise and can read coldly - ask your care team to explain anything that is unclear.

Ask your care team to explain anything that is unclear.

  1. 01 Header

    Indication, Prague C&M and dysplasia grade

    Why ablation was done, the length of the Barrett’s segment before treatment (C and M measurements) and the pathologist-confirmed dysplasia grade.

  2. 02 Technique

    Platform, energy setting and coverage

    Which catheter was used (360 Express, 90, Ultra), the energy density in J/cm², number of applications and the segment length treated.

  3. 03 Findings

    Response and any residual disease

    What the follow-up endoscopy showed - complete eradication of dysplasia, complete eradication of intestinal metaplasia, or residual tongues that need further focal RFA.

  4. 04 Impression

    Medication, next session and surveillance

    Read this first: PPI dose, sucralfate course, when the next ablation or surveillance endoscopy is booked, and any red flags to watch for at home.

Recognised by major UK insurers

BupaAXA HealthVitalityAvivaWPACignaHealixBupaAXA HealthVitalityAvivaWPACignaHealixBupaAXA HealthVitalityAvivaWPACignaHealix

RFA for Barrett’s with confirmed dysplasia is usually covered as a medically indicated treatment. Combined EMR + RFA and multi-session CE-IM programmes are typically pre-authorised on histology and the endoscopist’s plan.

Frequently asked

Everything we get asked about RFA for Barrett’s.

Quick answers on dysplasia, sessions, strictures, cost and long-term surveillance.

  • What is radiofrequency ablation for Barrett’s oesophagus?

    It is a day-case endoscopic treatment that delivers a precisely controlled thermal burn to the abnormal Barrett’s lining. Under sedation, a HALO or Barrx catheter is passed through a standard gastroscope and applied to the segment, destroying the metaplastic cells so that normal squamous lining regrows in their place.

  • Who should have RFA rather than surveillance?

    UK and BSG guidance recommends ablation for confirmed low-grade dysplasia, high-grade dysplasia without a visible lesion, and after EMR of intramucosal cancer. Non-dysplastic Barrett’s is still managed by surveillance and PPI in most units, not ablation.

  • How many sessions will I need?

    Most patients need between two and four sessions spaced 2–3 months apart. Long-segment Barrett’s (C≥5) typically needs more; short tongues can be cleared in a single focal treatment. Complete eradication of intestinal metaplasia is achieved in around 80–90 percent of patients by the end of the programme.

  • Is it painful and how long does it take?

    The procedure itself takes 20–40 minutes and you are sedated throughout. Afterwards, retrosternal ache and painful swallowing for 3–5 days are common. A liquid then soft diet, high-dose PPI, sucralfate suspension and paracetamol usually handle it comfortably.

  • What are the risks?

    The main risk is a benign oesophageal stricture, which happens in 5–8 percent of patients and almost always responds to one or two balloon dilatations. Bleeding is uncommon, perforation very rare (under 1 in 500). Around 5 percent of patients develop buried intestinal metaplasia - which is why surveillance biopsies continue after CE-IM.

  • How much does private RFA cost in the UK?

    Roughly £4,500–£7,000 for a single circumferential session, £3,000–£5,000 for a focal touch-up, and £12,000–£22,000 for a full three- to four-session programme to CE-IM. Combined EMR + RFA runs £5,500–£9,000.

  • Will I still need PPI and surveillance afterwards?

    Yes. Twice-daily proton-pump inhibitor is standard for life after ablation to control the reflux that caused the Barrett’s in the first place. Surveillance gastroscopy with biopsies is done at 3, 6 and 12 months, then annually - recurrence runs at around 5–8 percent per year and is usually treated with one further focal session.

  • How is RFA different from an oesophagectomy?

    RFA is a day-case endoscopic burn that removes the abnormal lining but leaves the oesophagus intact. Oesophagectomy is major thoracic surgery with a mortality of 2–5 percent and life-changing effects on eating. For high-grade dysplasia and intramucosal cancer, endoscopic pathways - EMR then RFA - are now the first choice wherever the disease is confined to the mucosa.

Related treatments

Looking for something else?